bluebird bio Announces Pricing of Public Offering of Common Stock
July 10, 2014
PDF 233.8 KB
DownloadInnovative gene therapies for severe genetic disorders from a broadly applicable gene therapy platform.
Bluebird Bio is developing innovative gene therapies for severe genetic disorders from a broadly applicable gene therapy platform.
bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/ sickle cell anemia. The company was formerly known as Genetix Pharmaceuticals.
Industry
Biotech
Status
Realised
Location
US